Becton Dickinson Divests Surgical Instrumentation Segment to Steris for $540 Million
By Adriano Marchese
Medical technology company Becton Dickinson will sell its surgical instrumentation platform to Ireland-based medical equipment company Steris for $540 million.
The Franklin Lakes, New Jersey-based company said the divestiture of its surgical instrumentation, laparoscopic instrumentation and sterilization container assets is part of the company's push to simplify its product portfolio and manufacturing network, and is a critical part of its strategy going into 2025.
"This strong value-creating transaction supports the achievement of BD's 2025 financial goals, including revenue growth and margin expansion," the company said.
The divestiture will include products provided under the brands V. Mueller, Snowden-Pencer and Genesis as well as three plants located in St. Louis, Missouri, Cleveland, Ohio and one in Tuttlingen, Germany.
Becton Dickinson said that it expects about 360 employees that maintain and support the platform will transfer over to Steris.
On the other side of the deal, Steris said that the acquisition strengthens, complements and expands the company's product offerings within the healthcare segment.
Steris projects that annual revenue for these assets is projected to contribute about $170 million to Becton Dickinson's fiscal 2023 results with adjusted earnings before interest and taxes of approximately $45 million.
Steris also anticipates to qualify for a tax benefit related to tax deductible goodwill with a present value of about $60 million.
The transaction is expected to close before Sept. 30 of this year.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
June 20, 2023 08:47 ET (12:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?